| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000005483 |
| Receipt No. | R000006504 |
| Scientific Title | Randomized trial on the effect of non-calcium-containing phosphate binder lanthanum carbonate on vascular calcification in hemodialysis patients |
| Date of disclosure of the study information | 2011/04/30 |
| Last modified on | 2019/12/09 (Ver. 9) |
| Basic information | ||
| Public title | Randomized trial on the effect of non-calcium-containing phosphate binder lanthanum carbonate on vascular calcification in hemodialysis patients | |
| Acronym | Randomized trial on the effect of non-calcium-containing phosphate binder lanthanum carbonate on vascular calcification in hemodialysis patients | |
| Scientific Title | Randomized trial on the effect of non-calcium-containing phosphate binder lanthanum carbonate on vascular calcification in hemodialysis patients | |
| Scientific Title:Acronym | Randomized trial on the effect of non-calcium-containing phosphate binder lanthanum carbonate on vascular calcification in hemodialysis patients | |
| Region |
|
|
| Condition | ||
| Condition | end-stage renal disease | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To compare the difference of vascular calcification between lanthanum carbonate and calcium carbonate administered group in hemodialysis |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Phase IV |
| Assessment | |
| Primary outcomes | Abdominal aortic calcification (Progression of abdominal aortic calcification volume detected by computed tomography image for renal carcinoma screening) |
| Key secondary outcomes | 1) Phosphorus and calcium level achievement rate as defined by the Japanese Society for Dialysis Therapy guideline
2) Incidence of hypercalcemia ( defined as corrected serum calcium>10.5mg/dl) 3) Incidence of secondary hyperparathyroidism (defined as i-PTH>240pg/ml) 4) Performance rate of PTx and PEIT 5) BAP(ALP), i-PTH, BAP/i-PTH 6) Arterial stiffness change (CAVI, PWV, ABI) 7) Safety |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -but assessor(s) are blinded |
| Control | Active |
| Stratification | NO |
| Dynamic allocation | YES |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Lanthanum carbonate treatment (Enrollment: 1 year, Follow-up: 3 years, Extension period:
2 years) |
|
| Interventions/Control_2 | Calcium carbonate treatment ((Enrollment: 1 year, Follow-up: 3 years, Extension period:
2 years) |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Hemodialysis patients
2) SerumP>6.0mg/dl and taking Phosphate binder in Hyperphosphosphataemia. 3) Hemodialysis for more than 6 mo, less than 5 years 4) Men or women >=20 years of age 5) Patients with written IC |
|||
| Key exclusion criteria | 1) Contraindications to Ca carbonate and La carbonate
2) Severe GI disorders 3) History of obstructed bowels 4) History of IHD/stroke within 6 mo before randomization 5) Severe congestive heart failure 6) Severe liver dysfunction (AST or ALT greater than 3 times the upper limit of normal, hepatic cirrhosis) 7) Severe malnutrition 8) Malignancy of any type within the last five years 9) Severe infectious disease within 3 mo before randomization 10) Pregnant or possibly pregnant women and women on lactation 11) Ineligible patients according to the investigators judgment |
|||
| Target sample size | 300 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Saitama Medical School | ||||||
| Division name | Department of Nephrology | ||||||
| Zip code | 350-0495 | ||||||
| Address | 38 Morohongo Moroyama-machi, Iruma-gun, Saitama, Japan | ||||||
| TEL | +81-49-276-1612 | ||||||
| iromichi@saitama.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Saitama Medical School | ||||||
| Division name | Department of Nephrology | ||||||
| Zip code | 350-0495 | ||||||
| Address | 38 Morohongo Moroyama-machi, Iruma-gun, Saitama, Japan | ||||||
| TEL | +81-49-276-1612 | ||||||
| Homepage URL | |||||||
| iromichi@saitama.ac.jp | |||||||
| Sponsor | |
| Institute | Department of Nephrology |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Saitama Medical School |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Saitama Medical University |
| Address | 38 Morohongo, Moroyama-machi,Iruma-gun, Saitama |
| Tel | 0492761354 |
| hirb@saitama-med.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 埼玉医科大学病院 入間台クリニック 岡病院 武蔵嵐山病院 くぼしまクリニック |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | Information other than what is described on this site is not open to the public. |
| Publication of results | Unpublished |
| Result | |||||||
| URL related to results and publications | Information other than what is described on this site is not open to the public. | ||||||
| Number of participants that the trial has enrolled | |||||||
| Results | No result |
||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results | |||||||
| Baseline Characteristics | No participants |
||||||
| Participant flow | No participants |
||||||
| Adverse events | None |
||||||
| Outcome measures | None |
||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006504 |